Responses
Regular and Young Investigator Award Abstracts
Cellular Therapies
379 Epi-RTM P2 protocol produces a scalable polyclonal TIL product with a greater expansion success rate across hot and cold tumors in shorter culture time
Compose a Response to This Article
Other responses
No responses have been published for this article.
